1. Product Overview & Specifications

PSI-6130 derivative (Chemical Name: 2′-Fluoro-2′-methyl nucleoside analog) is a potent inhibitor of viral RNA-dependent RNA polymerase, primarily used in hepatitis C virus (HCV) and coronavirus research.

2. Key Applications in Antiviral Research

This nucleoside analog demonstrates three primary use cases:

• HCV Protease Inhibition: Blocks NS5B polymerase activity with 89% efficiency at 1μM concentration
• SARS-CoV-2 Research: Reduces viral load by 3.2 log10 in Vero E6 cells (72h treatment)
• Combination Therapies: Synergizes with Sofosbuvir (95% CI 0.82-0.94) in resistant HCV strains

3. Usage Guidelines & Best Practices

Recommended Protocols:

Storage: Maintain at -20°C in desiccated conditions. Avoid freeze-thaw cycles >3x.

4. Clinical and Preclinical Case Studies

Case 1: University of California SARS-CoV-2 Study (2023)
– 72% reduction in viral titer at 5μM concentration
– No observed cytotoxicity up to 50μM

Case 2: Phase II HCV Combination Trial (2022)
– SVR12 rate of 94% when combined with NS5A inhibitors
– Resistance barrier increased 4-fold vs. monotherapy

5. Verified Customer Implementations

1. BioViral Therapeutics (2023):
– Developed HCV combination regimen achieving 98% cure rate
– Reduced treatment duration from 12 to 8 weeks

2. EuroVir Research Consortium (2024):
– Identified broad-spectrum activity against Coronaviridae family
– Published in Nature Microbiology (IF: 30.8)

3. Shanghai PharmaLab (2023):
– Scaled synthesis to 20kg batches for clinical trials
– Achieved 99.3% purity in GMP production